Vanguard Portfolio Management’s Kyverna Therapeutics KYTX Stock Holding History

Vanguard Portfolio Management’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.51M	Buy	+282,189	New	+$2.51M	﹤0.01%	2667

Other funds holding KYTX

GGI

GordonMD Global Investments Beverely Hills, California $207M AUM

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IHG

Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Vanguard Portfolio Management's KYTX Position: Q2 2026 in Review

Vanguard Portfolio Management opened a new position in Kyverna Therapeutics (KYTX) in Q2 2026: 282,189 shares worth $2.51M. The stake represents ﹤0.01% of the portfolio and ranks #2667 among its holdings.

119 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

Vanguard Portfolio Management held 282,189 shares of Kyverna Therapeutics worth $2.51M as of Q2 2026.
Kyverna Therapeutics was a new Vanguard Portfolio Management position in Q2 2026.
Kyverna Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2667 holding.
119 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.